Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/52094
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoughead, E.en
dc.contributor.authorRamsay, E.en
dc.contributor.authorPriess, K.en
dc.contributor.authorBarratt, J.en
dc.contributor.authorRyan, P.en
dc.contributor.authorGilbert, A.en
dc.date.issued2009en
dc.identifier.citationPharmacoepidemiology and Drug Safety, 2009; 18(1):69-75en
dc.identifier.issn1053-8569en
dc.identifier.issn1099-1557en
dc.identifier.urihttp://hdl.handle.net/2440/52094-
dc.descriptionThe definitive version may be found at www.wiley.comen
dc.description.abstractPURPOSE: We aimed to determine the duration of first episode of therapy and overall therapy as well as time without treatment for bisphosphonates. METHODS: Data were extracted from Department of Veterans' Affairs (DVA) dataset for those with at least one dispensing for a bisphosphonate between April 2001 and April 2007. Episodes of use were determined as the number of treatment days between the first and last prescription plus 35 days once a dispensing gap of 105 days had been reached, or where no treatment gaps were recorded, the study end date. Kaplan-Meier analyses were undertaken for the first episode of use, overall duration and time without treatment. RESULTS: When considering only the duration of first episode, median bisphosphonate use was 1.19 years. The median duration extended to 3.27 years when all episodes of use were considered. Overall, 52.0% of subjects reached at least 3 years of treatment and 66.5% of existing users had a duration of at least 3 years. Median time without treatment was 1.65 years. Overall, 81% of the cohort had enough medicine dispensed to be considered adherent throughout their duration of use. CONCLUSION: Over 50% of subjects and 66% of existing users had duration consistent with the minimum recommended. Adherence within an episode was high. The focus for improving duration of bisphosphonate use should be on reducing the time without treatment, rather than adherence at the time of use. Studies assessing only the first episode of use in new users of medicines may underestimate duration.en
dc.description.statementofresponsibilityElizabeth E. Roughead, Emmae Ramsay, Kym Priess, John Barratt, Philip Ryan and Andrew L. Gilberten
dc.language.isoenen
dc.publisherJohn Wiley & Sons Ltden
dc.subjectHumans; Diphosphonates; Time Factors; Databases, Factual; Aged; Aged, 80 and over; Veterans; United States; Female; Male; Medication Adherence; Kaplan-Meier Estimateen
dc.titleMedication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonatesen
dc.typeJournal articleen
dc.identifier.rmid0020090167en
dc.identifier.doi10.1002/pds.1687en
dc.identifier.pubid39315-
pubs.library.collectionPublic Health publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Public Health publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.